Essence pharmaceuticals terminates the development of two human monoclonal antibody products

In the evening of February 19th, the essence pharmaceutical announced that it signed the cooperation and authorization agreement with Kadmon Corporation and LLC in October 29, 2015 to cooperate in the development of VEGFR-2 monoclonal antibody and PDL-1 monoclonal antibody product But up to now, the essence of pharmaceuticals said that the two products are still in the pre clinical research and development stage, and the research results and progress do not meet the expectations Considering the actual situation of market competition, it is expected that the benefits of the project are not obvious and the project faces great risks After consultation with kadmon company of the United States, it is decided to terminate the R & D work of the project New drug R & D is a high investment and high-risk project, and the R & D risk is inevitable The company is adjusting the R & D project structure, focusing more on the R & D of proprietary Chinese medicine and classic chemicals, and the secondary development of existing varieties, so as to improve the company's core competitiveness Adorable adorable